You had searched for:
There were no results matching the query.
You can also browse the topics below to find what you are looking for.
FOCUS: was the largest study of its kind (N=838) in patients with inadequate response to 2 or more classes of prior preventive treatments1
Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)#
3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use2
2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins2
#For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.
Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)2
Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo2